Claims for Patent: 5,668,002

Summary for Patent: 5,668,002

Title:	DNA and polypeptide for tumor-associated antigen CO-029
Abstract:	The human tumor-associated antigen CO-029 is a monoclonal antibody-defined, 27-34 kDa cell surface glycoprotein. A full-length cDNA clone for CO-029 is described. When transiently expressed in COS cells, the cDNA clone directs the synthesis of an antigen reactive with monoclonal antibody CO-029 in mixed hemadsorption and immunoblot assays. Sequence analysis reveals that CO-029 belongs to a family of cell surface antigens which includes the melanoma-associated antigen ME491, the leukocyte cell surface antigen CD37, and the Sm23 antigen of the parasitic helminth Schistosoma mansoni.
Inventor(s):	Linnenbach; Alban J. (Philadelphia, PA), Koprowski; Hilary (Wynnewood, PA), Szala; Stanislaw (Philadelphia, PA)
Assignee:	The Wistar Institute (Philadelphia, PA)
Application Number:	07/575,567
Patent Claims:	1. An intron-free DNA molecule which encodes a tumor-associated antigen, said antigen immunoreactive with monoclonal antibody CO-029. 2. The intron-free DNA molecule of claim 1 wherein the tumor associated antigen has a protein molecular weight of 26,044. 3. The intron-free DNA molecule of claim 1 wherein the amino acid sequence of said antigen is shown in FIG. 3. 4. The intron-free DNA molecule of claim 1 wherein the nucleic acid sequence is shown in FIG. 3. 5. The intron-free DNA molecule of claim i which is covalently linked to a vector which can replicate in E. coli. 6. The intron-free DNA molecule of claim 1 which causes expression of a protein in COS cells immunoreactive with monoclonal antibody CO-029. 7. An intron-free DNA molecule comprising a nucleic acid sequence shown in FIG. 3. 8. An intron-free DNA molecule which hybridizes under stringent conditions to DNA having the sequence shown in FIG. 3. 9. An intron-free DNA molecule which codes for a polypeptide consisting essentially of an extracellular domain of the CO-029 antigen. 10. A polypeptide consisting essentially of an extracellular domain of the CO-029 antigen. 11. The polypeptide of claim 10 wherein the domain comprises amino acids 34 to 57 of CO-029. 12. The polypeptide of claim 10 wherein the domain comprises amino acids 110 to 205 of CO-029. 13. The polypeptide of claim 10 which is covalently linked to an amino acid sequence which causes said polypeptide to be secreted from cells. 14. A preparation of CO-029 antigen which is entirely free of other human proteins. 15. The preparation of claim 14 wherein the antigen is made in non-human cells which have been transformed with a DNA molecule encoding said antigen. 16. Non-human cells transformed with a DNA molecule encoding CO-029 antigen. 17. Cells transformed with the DNA molecule of claim 1. 18. Cells transformed with the DNA molecule of claim 7. 19. Cells transformed with the DNA molecule of claim 8. 20. Cells transformed with the DNA molecule of claim 9.

Details for Patent 5,668,002

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26